Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Post by goldmembon Jun 30, 2017 9:36am
56 Views
Post# 26423460

KALY.vn

KALY.vn
"among ten patients with steroid-refractory acute (Grade 3-4) GvHD, 90% achieved either complete remission (“CR”) or a near-complete response with CBD" 

Amazing results which were released in February, this was for phase 2a and the FDA released this regarding the study

"The U.S. FDA has recommended that the sponsor of the study apply for both Breakthrough Therapy and Fast Track Designations, each of which could accelerate the approval process."

This shows there is real value to their CBD cure for GvHD which is a major occurrence with Bone marrow or stem cell transplants. This occurs when the white blood cells attack the new cells. 

This could be a game changer in the 
pharmaceutical market!

Currently 14 cents! 

Buy now, while the shares are still so cheap!

Goldmemb
Bullboard Posts